Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
EyePoint Pharmaceuticals, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of OAG or OHT in each eye (OAG in one eye and OHT in the fellow eye is acceptable)
Must be receiving treatment with a stable regimen of topical prostaglandin eyedrop for a minimum of 2 weeks prior to the Screening Visit; may be taking one additional IOP lowering eyedrop
IOP of ≥ 18 mmHg and ≤ 27 mmHg in one eye or both eyes at Screening visit
Following 4 week washout period, IOP ≥ 24 mmHg and \< 36 mmHg at 08:00 hour and IOP ≥ 22 mmHg and \< 36 mmHg in both eyes at 10:00, 12:00 and 16:00 hours.
You may not be if
Clinically significant ocular disease which might interfere with interpretation of the study efficacy endpoints or with safety assessments
Pseudoexfoliation or pigment dispersion component glaucoma
History of angle closure glaucoma, or narrow angles or with evidence of peripheral anterior synechiae (PAS) ≥ 180 degrees by gonioscopy within 6 months prior to Screening
Intraocular pressure ≥ 36 mmHg
Cup/disc ratio of \> 0.8 in either eye
Severe visual field defect or significant defect (sensitivity of ≤ 10dB) within 10 degrees of fixation in either eye
Clareo Health | Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
